During the past decade, L V Prasad Eye Institute conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 3 clinical trials were completed, i.e. on average, 23.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "L V Prasad Eye Institute" #1 sponsor was "L.V. Prasad Eye Institute" with 3 trials, followed by "Lux Biosciences, Inc." with 3 trials sponsored, "Pro Top & Mediking Company Limited" with 2 trials sponsored, "Asia Cornea Society" with 1 trials sponsored and "Association for Innovation and Biomedical Research on Light and Image" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "L V Prasad Eye Institute" #1 collaborator was "Belfast Health and Social Care Trust" with 1 trials as a collaborator, "Brighten Optix Corporation" with 1 trials as a collaborator, "Clearly" with 1 trials as a collaborator, "Johns Hopkins University" with 1 trials as a collaborator and "L.V. Prasad Eye Institute" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "L V Prasad Eye Institute" are "Panuveitis" (4 trials), "Corneal Scars and Opacities" (2 trials), "Glaucoma" (2 trials), "Uveitis, Intermediate" (2 trials) and "Uveitis, Posterior" (2 trials). Many other conditions were trialed in "L V Prasad Eye Institute" in a lesser frequency.

Most popular intervention types in "L V Prasad Eye Institute" are "Drug" (10 trials), "Device" (6 trials), "Other" (4 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "LX211" (3 trials), "OculusGen Biodegradable Collagen Matrix Implant" (2 trials), "Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)" (1 trials) and "DE-109 Intravitreal Injections" (1 trials). Other intervention names were less common.

The vast majority of trials in "L V Prasad Eye Institute" are 20 trials for "All" genders.

Currently, there are NaN active trials in "L V Prasad Eye Institute". 2 are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in L V Prasad Eye Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in L V Prasad Eye Institute, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".